Navigation Links
Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
Date:12/7/2007

HOPKINTON, Mass., Dec. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Kenneth L. Rice Jr., Executive Vice President and Chief Financial Officer of Alseres Pharmaceuticals, Inc., will be presenting a company overview at the New York Society of Security Analysts' 11th Annual Biotech/Specialty Pharma Conference, December 12th, 2007.

The New York Society of Security Analysts' 11th Annual Biotech/Specialty Pharma Conference hosts many of the industry's most innovative small- and micro-cap companies to discuss their plans to invent, develop, research and market important new drugs, diagnostics and delivery technologies. For more information on the conference and speaking companies please go to http://www.nyssa.org. Alseres' presentation will not be web cast at this conference.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
2. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
3. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
5. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... AL (PRWEB) , ... September 21, 2017 , ... ... provider with offices serving communities in northern Alabama and Georgia, is embarking on ... cancer prevention by utilizing modern early detection methods. , US Breast Cancer ...
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections ... is now accredited by The Joint Commission for chemical dependency and behavioral health ... certifies U.S. health care organizations that meet the commission’s rigorous standards. Accreditation by ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete Coatings announced ... that rely on safety and cleanliness. This unique flooring system uses silver ion ... used for centuries for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... providing a voice for people who have kidney disease. The theme “Describe a ... share their stories. Entrants needed to meet only one qualification— to have ...
(Date:9/20/2017)... (PRWEB) , ... September 20, ... ... a software company specializing in medical device compliance and commercialization, has just ... risk management activities. , FDA is more adamant than ever about medical ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, ... Pinnacle Professional Member in recognition of his contributions to ... serves as a Nephrologist at the practice of Kidney ... medicine, kidney care and hypertension solutions. He has worked ... years of career experience, as well as expertise in ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology: